HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Markovic–Plese, S. Articles by McFarland, H. F. Search for Related Content PubMed PubMed Citation Articles by Markovic–Plese, S. Articles by McFarland, H. F. Related Collections All Clinical trials Clinical trials Observational study (Cohort, Case control) Multiple sclerosis

Longitudinal MRI study

The effects of azathioprine in MS patients refractory to interferon ß-1b

From the Neuroimmunology Branch (Drs. Markovic–Plese, Bielekova, Leist, Martin, and McFarland) and Laboratory of Diagnostic Radiology Research (Drs. Kadom and Frank), National Institute of Neurological Diseases and Stroke, NIH, Bethesda, MD.

Address correspondence and reprint requests to Dr. H.F. McFarland, Neuroimmunology Branch, National Institute of Neurological Diseases and Stroke, Bldg. 10, Rm. 5B-16, 10 Center Dr., Bethesda, MD 20892-1400; e-mail: henrymcf{at}helix.nih.gov

An open-label study was performed to assess the effectiveness of oral azathioprine (AZA) on augmenting the response to interferon ß-1b (IFNß-1b) in patients with treatment-refractory relapsing–remitting MS. Six IFNß-1b-treated MS patients with continued disease activity were studied on IFNß-1b and AZA therapy for a median period of 15 months. A 69% reduction in the number of contrast-enhancing lesions was observed during the combination therapy (p = 0.002).

This article has been cited by other articles:

				N. D. Richert, T. Howard, J. A. Frank, R. Stone, J. Ostuni, J. Ohayon, C. Bash, and H. F. McFarland Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis Neurology, February 28, 2006; 66(4): 551 - 556. [Abstract] [Full Text] [PDF]

				L. Massacesi, A. Parigi, A. Barilaro, A. M. Repice, G. Pellicano, A. Konze, G. Siracusa, R. Taiuti, and L. Amaducci Efficacy of Azathioprine on Multiple Sclerosis New Brain Lesions Evaluated Using Magnetic Resonance Imaging Arch Neurol, December 1, 2005; 62(12): 1843 - 1847. [Abstract] [Full Text] [PDF]

				E. M. Frohman, O. Stuve, E. Havrdova, J. Corboy, A. Achiron, R. Zivadinov, P. S. Sorensen, J. T. Phillips, B. Weinshenker, K. Hawker, et al. Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations Arch Neurol, October 1, 2005; 62(10): 1519 - 1530. [Abstract] [Full Text] [PDF]

				M Pulicken, C N Bash, K Costello, A Said, C Cuffari, J L Wilterdink, J M Rogg, P Mills, and P A Calabresi Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis Multiple Sclerosis, April 1, 2005; 11(2): 169 - 174. [Abstract] [PDF]

				D. R. Jeffery Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis Neurology, December 28, 2004; 63(12_suppl_6): S41 - S46. [Abstract] [Full Text]

				R. Bakshi, G. J. Hutton, J. R. Miller, and E.-W. Radue The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S3 - S11. [Abstract] [Full Text]

Correspondence: